Tenon Medical, Inc. (TNON) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Tenon Medical, Inc. is a medical device company focused on the U.S. market, developing and commercializing The Catamaran™ SI Joint Fusion System for the treatment of sacroiliac joint disorders. The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Q2 2024 (3 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $564,000 | $1,290,000 | $901,000 | $1,620,000 |
| Gross Profit | $245,000 | $568,000 | $470,000 | $940,000 |
| Gross Margin | 43% | 44% | 52% | 58% |
| Net Loss | $(2,769,000) | $(6,385,000) | $(3,826,000) | $(7,402,000) |
| Operating Expenses | $3,102,000 | $7,102,000 | $4,342,000 | $8,318,000 |
| Cash and Equivalents (End of Period) | $7,846,000 (as of June 30, 2025) | |||
| Accumulated Deficit | $(75,131,000) (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 37% in Q2 2025 compared to Q2 2024, and 20% on a year-to-date basis. Management attributes this to a decrease in the number of surgical procedures performed, while implants per procedure remained relatively constant.
- Margin Compression: Gross margin declined from 52% to 43% in Q2 and from 58% to 44% YTD. This was driven by the absorption of production overhead costs in 2024 and lower operating leverage due to reduced volume.
- Expense Reduction: Total operating expenses decreased 29% in Q2 and 15% YTD compared to the prior year. Significant reductions were seen in General and Administrative expenses (down 32% in Q2) and Research and Development (down 29% in Q2), primarily due to lower stock-based compensation and professional fees.
- Liquidity Improvement: Cash and cash equivalents increased from $6.5 million at year-end 2024 to $7.8 million at June 30, 2025, driven by net cash provided by financing activities of $6.2 million in the first half of 2025.
Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months. Current cash reserves are insufficient to fund operations without additional capital.
- Capital Raising: The company plans to raise additional capital through public or private equity offerings, debt financings, or collaborations. In the first half of 2025, the company raised approximately $7 million through securities purchase agreements and a warrant inducement transaction.
- Subsequent Acquisitions: Following the reporting period, on August 1 and August 4, 2025, the company completed two asset acquisitions:
- SImmetry Acquisition: Acquired assets from SiVantage, Inc. related to sacropelvic fixation. Consideration included cash, stock, royalties, and deferred payments.
- SIMPL Acquisition: Acquired assets from SIMPL Medical, LLC related to posterior sacroiliac implant technology. Consideration is primarily royalty-based.
- Internal Controls: The company disclosed a material weakness in internal controls over financial reporting due to a lack of segregation of duties, resulting in disclosure controls being deemed ineffective.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the explicit "substantial doubt" regarding going concern status.
- Acquisition Integration: Review the details of the SImmetry and SIMPL acquisitions (closed post-period) to understand the impact on future revenue streams and royalty obligations.
- Revenue Drivers: Monitor surgical procedure volumes and reimbursement rates, as revenue is highly sensitive to case volume.
- Dilution Risk: Assess the potential dilution from outstanding warrants (over 5.9 million shares) and convertible preferred stock (over 340,000 shares) which are currently anti-dilutive.
- Internal Controls: Track progress on remediation of the material weakness regarding segregation of duties.